

LIBOCARE MEDICAL TRADE PRIVATE LIMITED  
CIN :- U51909UP2021PTC152609  
Shop No. 5, Dharampali, Bhoja Market,  
Sector-27 Noida Gautam Buddha Nagar UP 201301  
Balance Sheet as at 31 March, 2023  
(All amount in Rupees Thousands, unless otherwise stated)

Particulars	Note No.	As at 31 March, 2023	As at 31 March, 2022
<b>A. EQUITY AND LIABILITIES</b>			
<b>1 SHAREHOLDERS' FUNDS</b>			
a. Share capital	3	1,000	1,000
b. Reserves and surplus	4	(170)	(85)
		<b>830</b>	<b>915</b>
<b>2 CURRENT LIABILITIES</b>			
a. Trade payables			
- Total outstanding dues of micro enterprises and small enterprises		-	-
- Total outstanding dues of creditors other than micro enterprises and small enterprises	5	153	85
b. Other current liabilities	6	17	-
		<b>170</b>	<b>85</b>
<b>Total</b>		<b>1,000</b>	<b>1,000</b>
<b>B. ASSETS</b>			
<b>3 CURRENT ASSETS</b>			
a. Cash and cash equivalents	7	-	
b. Other current assets	8	1,000	1,000
		<b>1,000</b>	<b>1,000</b>
<b>Total</b>		<b>1,000</b>	<b>1,000</b>
<b>Summary of significant accounting policies</b>	2		

The accompanying notes are an integrated part of the financial statements

As per our report of even date attached

For Brahmayya & Co.  
Chartered Accountants  
Firm Registration No.: 0005115

For and on behalf of the Board of Directors  
Libocare Medical Trade Private Limited

N. Venkata Suneel  
Partner  
Membership No: 223688

Simon Mitterer  
Director  
DIN:09329653

Garvit Aggarwal  
Director  
DIN:08593294

Place : Gurugram  
Date: 29 September 2023

Place : Tirol, Austria  
Date: 29 September 2023

Place : Haryana, India  
Date: 29 September 2023

LIBOCARE MEDICAL TRADE PRIVATE LIMITED  
CIN :- U51909UP2021PTC152609  
Shop No. 5, Dharampali, Bhoja Market,  
Sector-27 Noida Gautam Buddha Nagar UP 201301  
Statement of Profit and Loss For the year Ended 31 March, 2023  
(All amount in Rupees Thousands, unless otherwise stated)

Particulars		For the year ended 31 March 2023	For the period September 22, 2021 to March 31, 2022
<b>1 INCOME</b>			
Revenue from operations	9	-	-
<b>TOTAL INCOME</b>		<u>-</u>	<u>-</u>
<b>2 EXPENSES</b>			
Other expenses	10	85	85
<b>TOTAL EXPENSES</b>		<u>85</u>	<u>85</u>
<b>3 Profit / (Loss) before tax (1-2)</b>		<u>(85)</u>	<u>(85)</u>
<b>4 Tax expense:</b>			
a. Current tax			-
b. Deferred Tax Expenses			-
		<u>-</u>	<u>-</u>
<b>5 Profit/Loss for the year (3-4)</b>		<u>(85)</u>	<u>(85)</u>
<b>6 Profit/(Loss) Per Share</b>			
(Nominal value of Rs. 10 each)			
Basic and diluted	11	(0.85)	(1.62)
<b>Summary of significant accounting policies</b>	2		

The accompanying notes are an integrated part of the financial statements

As per our report of even date attached

For Brahmayya & Co.  
Chartered Accountants  
Firm Registration No.: 000511S

For and on behalf of the Board of Directors  
Libocare Medical Trade Private Limited

N. Venkata Suneel  
Partner  
Membership No: 223688

Simon Mitterer  
Director  
DIN:09329653

Garvit Aggarwal  
Director  
DIN:08593294

Place : Gurugram  
Date: 29 September 2023

Place : Tirol, Austria  
Date: 29 September 2023

Place : Haryana, India  
Date: 29 September 2023

**LIBOCARE MEDICAL TRADE PRIVATE LIMITED**  
**CIN :- U51909UP2021PTC152609**  
**Shop No. 5, Dharampali, Bhoja Market,**  
**Sector-27 Noida Gautam Buddha Nagar UP 201301**  
**Cash Flow Statement for the year ended 31 March, 2023**  
**(All amount in Rupees Thousands, unless otherwise stated)**

Particulars	As at 31 March, 2023	For the period September 22, 2021 to March 31, 2022
<b>A. Cash Flow from operating activities:</b>		
<b>Profit before Tax</b>	(85)	(85)
<b>Adjusted for changes in working capital:</b>		
Increase/ (Decrease) in Trade payables	68	85
Increase/(Decrease) in Other Current liabilities	17	-
<b>Cash generated from operations</b>	-	-
Income tax paid (Net of TDS)	-	-
<b>Net Cash from/ (used in) operating activities (A)</b>	-	-
<b>B. Cash Flow from investing activities:</b>		
<b>Net Cash from/ (used in) investing activities (B)</b>	-	-
<b>C. Cash Flow from financing activities:</b>		
<b>Net Cash generated from/ (used in) financing activities (C)</b>	-	-
<b>Net Increase in Cash &amp; Cash Equivalents (A+B+C)</b>	-	-
Cash and cash equivalents at the beginning of the year	-	-
<b>Cash and Cash Equivalents as at end of the year</b>	-	-
<b>Cash &amp; Cash Equivalents comprise</b>	<b>As at 31 March, 2023</b>	<b>As at 31 March, 2022</b>
Balances with bank in:		
Current account	-	-
	-	-

Summary of significant accounting policies 2

**Notes:**

1. The above cash flow statement has been prepared under the indirect method set out in Accounting Standard (AS-3) on "Cash Flow Statements" specified under Section 133 of the Companies Act, 2013. read together with Companies (Accounting Standards) Rules, 2021 (amended).

**For Brahmayya & Co.**

Chartered Accountants  
Firm Registration No.: 000511S

**For and on behalf of the Board of Directors**

**Libocare Medical Trade Private Limited**

**N. Venkata Suneel**

Partner  
Membership No: 223688

Place : Gurugram  
Date: 29 September 2023

**Simon Mitterer**

Director  
DIN:09329653

Place : Tirol, Austria  
Date: 29 September 2023

**Garvit Aggarwal**

Director  
DIN:08593294

Place : Haryana, India  
Date: 29 September 2023

**LIBOCARE MEDICAL TRADE PRIVATE LIMITED**

**CIN :- U51909UP2021PTC152609**

**Shop No. 5, Dharampali, Bhoja Market,**

**Sector-27 Noida Gautam Buddha Nagar UP 201301**

**Notes to Financial Statements for the year ended 31st March 2023**

**(All amount in Rupees Thousands, unless otherwise stated)**

**1 Corporate Information**

Libocare Medical Trade Private Limited (the Company) is a private limited company domiciled in India and incorporated under the Companies Act, 2013 on 22nd September 2021. The Company is operating under only one business segment i.e. trading in medical equipments.

**2 Summary of significant accounting policies**

**a) Basis of Preparation**

The financial statements of the company have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP). The company has prepared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013, read together with the Companies (Accounting Standards) Amendment Rules, 2021 (amended). The financial statements have been prepared on an accrual basis and under the historical cost convention. The accounting policies have been consistently applied by the Company.

The Company is a Small and Medium Sized Company (SMC) as defined in the General Instructions in respect of Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 ('Act'). Accordingly, the Company has complied with the Accounting Standards as applicable to a Small and Medium Sized Company, read together with the other requirements of the Act.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of services rendered by the company and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non current classification of assets and liabilities.

**b) Use of Estimates**

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

**c) Property, Plant & Equipment**

There are no fixed assets during the year ended March 31, 2023

**d) Revenue Recognition**

There is no revenue during the year ended March 31, 2023

**e) Earnings per Share**

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average numbers of equity shares are adjusted for events such as bonus issue, bonus element in the rights issue, share split and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

**f) Contingent liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

**g) Provisions**

A provision is recognized when the Company has a present obligation as a result of past event, the settlement of which is expected to result in an outflow of resources embodying economic benefits and reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each Balance Sheet date and adjusted to reflect the current best estimate.

Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of profit and loss net of any reimbursement.

**h) Cash and cash equivalents**

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term investments with an original maturity of twelve months or less.

**LIBOCARE MEDICAL TRADE PRIVATE LIMITED**

**CIN :- U51909UP2021PTC152609**

**Shop No. 5, Dharampali, Bhoja Market,**

**Sector-27 Noida Gautam Buddha Nagar UP 201301**

**Notes to Financial Statements for the year ended 31st March 2023**

**(All amount in Rupees Thousands, unless otherwise stated)**

**i) Foreign currency transactions**

*Initial recognition*

Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction. Measurement of foreign currency monetary items at the Balance Sheet date. Foreign currency monetary items of the Company outstanding at the Balance sheet date are restated at the period-end rates.

*Treatment of exchange differences*

Exchange differences arising on settlement / restatement of short-term foreign currency monetary assets and liabilities of the Company are recognized as income or expense in the Statement of Profit and Loss.

**j) Current and Deferred Tax**

Tax expense for the year comprising current and deferred tax is included in determining the net profit for the year.

**Current tax**

Provision for current tax comprises of current income tax and is made after taking into consideration benefits admissible under the provisions of the Income Tax Act, 1961. Income taxes are accrued in the same period the related revenue and expenses arise.

**Deferred tax**

Provision for deferred tax (reflecting the tax effects of timing differences between accounting income & taxable income for the period) is determined in accordance with Accounting Standard-22 issued by Ministry of Corporate Affairs. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognized using the tax rates that have been enacted or substantially enacted by the balance sheet date.

Deferred Tax Assets are recognized on carry forward losses and unabsorbed depreciation to the extent that there is virtual certainty that sufficient future taxable income will be available against which such Deferred Tax Assets can be realized.

LIBOCARE MEDICAL TRADE PRIVATE LIMITED  
CIN :- U51909UP2021PTC152609  
Shop No. 5, Dharampali, Bhoja Market,  
Sector-27 Noida Gautam Buddha Nagar UP 201301  
Notes to Financial Statements for the year ended 31st March 2023  
(All amount in Rupees Thousands, unless otherwise stated)

### 3 SHARE CAPITAL

Particulars	As at 31 March 2023	As at 31 March 2022
<b>Authorized Shares</b>		
1,00,000 (March 31, 2022: 1,00,000 of Rs. 10 each) equity shares of Rs. 10 each	1,000	1,000
	<b>1,000</b>	<b>1,000</b>
<b>Issued, Subscribed and fully paid up #</b>		
1,00,000 (March 31, 2022: 1,00,000 of Rs. 10 each) equity shares of Rs. 10 each	1,000	1,000
	<b>1,000</b>	<b>1,000</b>
<b>Total issued and Subscribed share capital</b>	<b>1,000</b>	<b>1,000</b>

# Share are subscribed by the subscriber of Memorandum of Association; However, subscription amounts are unpaid as at 31st March, 2023.  
Further Refer Note 31.

#### (i) Details of shares held by each shareholder holding more than 5% shares :

Name of Shareholder	As at 31 March, 2023		As at 31 March, 2022	
	No. of Shares*	% Holding	No. of Shares*	% Holding
<b>Equity shares with voting rights</b>				
Simon Mitterer	99,999	99.99%	99,999	99.99%

#### (ii) Details of Shares held by promoters at the end of the year:

Promoter's Name	As at 31 March, 2023		As at 31 March, 2022	
	No. of Shares*	% Holding	No. of Shares*	% Holding
Simon Mitterer	99,999	99.99%	99,999	99.99%
Garvit Aggarwal**	1	0.01%	1	0.01%

\* In actual figures

\*\* Nominee of Mr. Simon Mitterer

Capital infusion by the subscribers to memorandum ( Simron Mitterer and Garvit aggarwal amounting to Rs 9,99,990 and 10 respectively) was not made till 31st March 2023.

#### Notes :

- (i) The Company has issued only one class of equity shares having par value of Rs. 10 per share. Each shareholder is entitled to one vote per share. The Dividend if proposed by the Board of Directors is subject to approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

### 4 RESERVES AND SURPLUS

Particulars	As at 31 March 2023	As at 31 March 2022
<b>Statement of Profit and Loss</b>		
i. Opening balance - Deficit	(85)	-
ii. Add : Profit /(Loss) for the year	(85)	(85)
iii. Closing balance - Deficit	<b>(170)</b>	<b>(85)</b>

LIBOCARE MEDICAL TRADE PRIVATE LIMITED  
CIN :- U51909UP2021PTC152609  
Shop No. 5, Dharampali, Bhoja Market,  
Sector-27 Noida Gautam Buddha Nagar UP 201301  
Notes to Financial Statements for the year ended 31st March 2023  
(All amount in Rupees Thousands, unless otherwise stated)

**5 Trade Payables**

Particulars	As at 31 March 2023	As at 31 March 2022
Trade Payables		
'Total outstanding dues to micro enterprises and small enterprises	-	-
'Total outstanding dues to creditors other than micro enterprises and small enterprises	153	85
	<b>153</b>	<b>85</b>

**As at 31 March 2023**

Particulars	Outstanding for following periods from due date of payment*				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Total outstanding dues of micro enterprises and small enterprises	-	-	-	-	-
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	153	-	-	-	153
<b>Total</b>	<b>153</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>153</b>

\* The above ageing schedule is outstanding from transaction date.

**As at 31 March 2022**

Particulars	Outstanding for following periods from due date of payment*				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Total outstanding dues of micro enterprises and small enterprises	-	-	-	-	-
(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	85	-	-	-	85
<b>Total</b>	<b>85</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>85</b>

\* The above ageing schedule is outstanding from transaction date.

**6 Other Current Liabilities**

Particulars	As at 31 March 2023	As at 31 March 2022
<b>Other payable</b>		
Statutory Dues	17	-
	<b>17</b>	<b>-</b>

**7 Cash And Cash Equivalents**

Particulars	As at 31 March 2023	As at 31 March 2022
Balance with bank:		
In current account	-	-
	<b>-</b>	<b>-</b>

**8 Other Current assets**

Particulars	As at 31 March 2023	As at 31 March 2022
Others *	1,000	1,000
	<b>1,000</b>	<b>1,000</b>

\* Represents receivable from the subscriber to memorandum of association

- The Company was incorporated on September 22, 2021 and equity shares were allotted to Simon Mitterer & Garvit Aggarwal, being the subscribers to the memorandum of association of the Company. The amount towards allotment of share capital has not been received during the period ended March 31, 2023. Accordingly in the year ended March 31, 2023, amount due towards share capital was disclosed as Share Application Money Receivable under "Other Current Assets".
- The Company received a full amount of subscription money on 14th June, 2023, i.e. after 180 days from incorporation.

LIBOCARE MEDICAL TRADE PRIVATE LIMITED  
CIN :- U51909UP2021PTC152609  
Shop No. 5, Dharampali, Bhoja Market,  
Sector-27 Noida Gautam Buddha Nagar UP 201301  
Notes to Financial Statements for the year ended 31st March 2023  
(All amount in Rupees Thousands, unless otherwise stated)

**9 Revenue from operations**

Particulars	For the Year ended March 31, 2023	For the period September 22,2021 to March 31, 2022
Sales of services	-	-
	-	-

**10 Other Expenses**

Particulars	For the Year ended March 31, 2023	For the period September 22,2021 to March 31, 2022
Legal and professional charges*	85	85
	<b>85</b>	<b>85</b>

\* Includes Auditor's remuneration as stated below:

Auditor's remuneration:

Particulars	For the Year ended March 31, 2023	For the period September 22, 2021 to March 31, 2022
Statutory audit*	85	85
Out of pocket expenses	-	-
	<b>85</b>	<b>85</b>

**11 Earnings Per Share**

Particulars	Unit	For the Year ended March 31, 2023	For the period September 22, 2021 to March 31, 2022
<u>Basic/Diluted</u>			
Profit/(Loss) for the year/period	Rupees	(85)	(85)
Weighted average number of equity shares outstanding during the year	Numbers	1,00,000	52,329
Nominal value per Equity Shares	Rupees	10	10
Basic/Diluted Earnings Per Share	Rupees	(0.85)	(1.62)

(i) There are no dilutive potential equity shares.

**12 Related party disclosures**

**a. List of related parties**

- i. Holding company NA
- ii Fellow Subsidiary NA

**i Key management personnel (KMP)\*\*\***

- a) Simon Mitterer (Director w.e.f. 22nd Sep 2021)
- b) Garvit Aggarwal (Director w.e.f. 22nd Sep 2021)

**b. Transactions with related parties :**

Particulars	For the Year ended March 31, 2023	For the period September 22, 2021 to March 31, 2022
Transactions during the year		

\*\*\*No remuneration has been paid/payable to key management personnel.



**LIBOCARE MEDICAL TRADE PRIVATE LIMITED**  
**CIN :- U51909UP2021PTC152609**  
**Shop No. 5, Dharampali, Bhoja Market,**  
**Sector-27 Noida Gautam Buddha Nagar UP 201301**  
**Notes to Financial Statements for the year ended 31st March 2023**  
**(All amount in Rupees Thousands, unless otherwise stated)**

**13 Expenditure in Foreign Currency**

The Company did not incur expenditure in foreign currency during the period from 01 April 2022 to 31 March 2023.

**14** The Company has not incurred expenses towards CIF value of imports in the current financial year.

**15 Operating leases: company as lessee**

The Company has not entered into any operating lease arrangements for any facilities and office premises.

**16 Unhedged foreign currency exposure**

The Company has not any Unhedged foreign currency exposure

**17 Earnings in Foreign Currency (accrual basis)**

The Company has not any earnings in Foreign Currency

**18 Earnings per share ('EPS')**

The Company does not have allotted any shares as at 31 March 2023.

**19 Auditors' remuneration (excluding applicable tax)**

Particulars	For the year ended 31 March 2023	For the period from 22 September 2021 to 31 March 2022
Statutory audit	85	85
	<b>85</b>	<b>85</b>

**20 Contingent liabilities & commitments**

The Company does not have any contingent liabilities, capital commitments and other commitments as at 31 March 2023.

**21 Employee benefit plans:**

The Company does not have any employees as at 31 March 2023.

**22 Income Taxes:**

The Company does not commenced any business as at 31 March 2023.

**23** The Company does not fall under the purview of Section 135 (Corporate social responsibility) of the Companies Act, 2013, therefore no money has been spent on CSR activities during the year.

**24 Other Statutory Requirement**

- i) Title deeds of Immovable Property not held in name of the Company - There is no immovable property (other than properties where the company is the lessee and the lease agreements are duly executed in the favor of the lessee), held by the company.
- ii) Details of Benami Property and its proceedings- Not applicable as there are no proceedings which have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.
- iii) Wilful Defaulter - Not applicable as the Company has no loans from Banks or Financial Institution and the Company has not been classified as a wilful defaulter.
- iv) Compliance with number of layers of companies - The company has no subsidiaries. Accordingly , provision of clause (87) of section 2 of the act read with the Companies (Restriction on number of Layers) Rules, 2017, is not applicable.
- v) Compliance with approved Scheme(s) of Arrangements - Not Applicable as the Company has no Scheme of Arrangements that has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013
- vi) Details of Crypto Currency or Virtual Currency - Not Applicable as the Company has not traded or invested in Crypto currency or Virtual Currency during the financial year
- vii) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income-tax Act, 1961.

**LIBOCARE MEDICAL TRADE PRIVATE LIMITED**  
**CIN :- U51909UP2021PTC152609**  
**Shop No. 5, Dharampali, Bhoja Market,**  
**Sector-27 Noida Gautam Buddha Nagar UP 201301**  
**Notes to Financial Statements for the year ended 31st March 2023**  
**(All amount in Rupees Thousands, unless otherwise stated)**

- viii) The Company has no transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956
- ix) The Company has not advanced or loaned or invested funds to any other persons or entities including foreign entities (intermediates) with the understanding that the intermediary shall
- (a) directly or indirectly lend or invest in other persons or entities in any manner whatsoever by or on behalf of the Company (ultimate beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.
- x) The Company has not received any fund from any persons or entities including foreign entities (intermediates) with the understanding that the intermediary shall
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (ultimate beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.
- xi) Charges against Registrar of Companies  
The Company has not created any charges that is registered with the Registrar of Companies in the year ended March 31, 2023.
- xii) Utilization of the borrowings availed from the banks and financial institutions : The company does not have any borrowings from banks and financial institutions as at the balance sheet date.
- xiii) The company had no intangible assets during the financial year ended March 31, 2023.
- xiv) The Company has not granted any loans or advances in the nature of loans to the KMP/related parties during the Financial Year 2022-2023.
- xv) The Company has not revalued any of its property, plant and equipment and intangible assets during the year.
- xvi) The Company does not have any borrowings from banks and financial institutions that are secured against current assets during the year.
- xvii) The Company does not have any Capital Work-in-Progress during the financial year.

**25 Segment Reporting**

The company does not commence any business operation. Hence, in accordance with Para 38 of AS-17 "Segment Reporting", separate disclosure for geographical and business segment is not required.

**26** There are no pending litigations against the company as at 31st March 2023.

**27** Figures have been rounded off to the nearest thousand (except where stated otherwise).

**28 Disclosure under the Micro, Small and Medium Enterprises Development Act, 2006 ("MSMED Act") are as follows:**

Particulars	As at March 31, 2023	As at March 31, 2022
i) Principal amount due to suppliers registered under the MSMED Act and remaining unpaid as at year end	-	-
ii) Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year	-	-
iii) Principal amounts paid to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
iv) Interest paid, under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
v) Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
vi) Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act.	-	-
vii) Interest accrued and remaining unpaid at the end of each accounting year	-	-
viii) Amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the MSMED Act	-	-

The above information regarding micro, small and medium enterprises have been determined to the extent such parties have been identified on the basis of information available with the Company.

**LIBOCARE MEDICAL TRADE PRIVATE LIMITED**  
**CIN :- U51909UP2021PTC152609**  
**Shop No. 5, Dharampali, Bhoja Market,**  
**Sector-27 Noida Gautam Buddha Nagar UP 201301**  
**Notes to Financial Statements for the year ended 31st March 2023**  
**(All amount in Rupees Thousands, unless otherwise stated)**

- 29** The Company was incorporated on 22nd September, 2021. Hence, the amounts presented for the financial year 2021-22 are from date of incorporation up to 31 March 2022.
- 30** The Annual General Meeting for the previous Financial year 2021-22 was held beyond the prescribed timelines under the Companies Act, 2013 subject to compounding by the concerned authority. Therefore, the company have to go for compounding for non-compliance under Section 441 for not conducting the AGM within the prescribed timelines under the Companies Act, 2013.
- 31** As per the provisions of Section 10A of the Companies Act, 2013, the Company was required to file Form INC-20A with the Registrar of Companies within a period of 180 days from the date of incorporation declaring that every subscriber to the memorandum has paid the value of the shares agreed to be taken by him However, the Company received a full amount of subscription money on 14th June, 2023, i.e. after 180 days from incorporation. Therefore, the company has to go for compounding for non-compliance with the provisions of Section 10A of the Companies Act, 2013.
- 32** As per the provisions of Section 117 read with MCA General Circular No. 14/2020 dated 08.04.2020, the Company was required to file Form MGT-14 with the Registrar of Companies for conducting EGM through video conferencing on 16<sup>th</sup> December, 2016. However, no intimation has been made to the registrar for the resolution passed in the said meeting. Therefore, the company has to go for Condonation of the above filing and intimate the ROC at the earliest.

**LIBOCARE MEDICAL TRADE PRIVATE LIMITED**

CIN :- U51909UP2021PTC152609

Shop No. 5, Dharampali, Bhoja Market,

Sector-27 Noida Gautam Buddha Nagar UP 201301

Notes to Financial Statements for the year ended 31st March 2023

(All amount in Rupees Thousands, unless otherwise stated)

**33. Ratios**

S. No.	Ratio	Numerator	Denominator	As at 31 March 2023	As at 31 March 2022	% of change
1	Current Ratio (1)	Current Assets	Current Liability	5.88	11.76	-50%
2	Debt-Equity Ratio	Debt	Equity	NA	NA	NA
3	Debt Service Coverage Ratio	Net Operating Income	Debt Service	NA	NA	NA
4	Return on Equity Ratio	Net Income	Shareholder's Equity	(0.10)	(0.09)	10%
5	Inventory Turnover Ratio	Cost of Goods Sold	Average Inventory	NA	NA	NA
6	Trade Receivables Turnover Ratio	Net Credit Sales	Average Receivables	NA	NA	NA
7	Trade Payables Turnover Ratio	Net Credit Purchases	Average Trade Payables	NA	NA	NA
8	Net Capital Turnover Ratio	Revenue	Average Working Capital	NA	NA	NA
9	Net Profit Ratio	Net Profit	Net Sales	NA	NA	NA
10	Return on Capital Employed	EBIT	Capital Employed	(0.10)	(0.09)	10%
11	Return on Investment	Net Profit	Net Investment= Net Equity	NA	NA	NA

(1) Due to increase in provision for expenses included in trade payable, the ratio decreased.

**As per our report of even date attached****For Brahmayya & Co.**

Chartered Accountants

Firm Registration No.: 000511S

**For and on behalf of the Board of Directors****Libocare Medical Trade Private Limited****N. Venkata Suneel**

Partner

Membership No: 223688

**Simon Mitterer**

Director

DIN:09329653

**Garvit Aggarwal**

Director

DIN:08593294

Place : Gurugram

Date: 29 September 2023

Place : Tirol, Austria

Date: 29 September 2023

Place : Haryana, India

Date: 29 September 2023